GlassScriptPhysician profile
Robert W Weller
NPI 1780685867
$2,435.06
in general payments reported to CMS, 2019-2025
15 companies · $487 in 2025
The $487 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $616 · 2020: $14.12 · 2022: $32.44 · 2023: $1,097 · 2024: $189 · 2025: $487.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $984 · Food and Beverage: $788.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $984.13 |
| Food and Beverage | $787.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pulmonx Corporation | $1,348.41 | 2020-2025 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Chartis Catheter |
| Olympus Corporation of The Americas | $616.40 | 2019 | |
| Intuitive Surgical, INC. | $129.80 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $63.20 | 2024-2025 | Dupixent |
| Mylan Specialty L.P. | $40.11 | 2024 | Yupelri |
| Astrazeneca Pharmaceuticals LP | $33.76 | 2024 | Fasenra |
| Vapotherm INC | $32.44 | 2022 | |
| Vifor Pharma, INC. | $25.00 | 2024 | Zemaira |
| Genzyme Corporation | $24.54 | 2025 | |
| Verona Pharma, INC. | $23.67 | 2025 | Ohtuvayre |
| Novartis Pharmaceuticals Corporation | $22.47 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.03 | 2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $17.90 | 2025 | Glassia |
| Genentech USA, INC. | $17.71 | 2024 | Xolair |
| Glaxosmithkline, LLC. | $17.62 | 2024 | Nucala |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Weller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.